Cargando...
Early clinical experience with the novel NMDA receptor antagonist CNS 5161
AIMS: To investigate the safety, tolerability and pharmacokinetics of the novel NMDA antagonist CNS 5161 in humans. Excessive activation of glutamate receptors, especially of the N-methyl-d-aspartate (NMDA) subtype has been associated with neuropathic pain, and brain damage caused by focal ischaemia...
Gardado en:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Blackwell Science Inc
2002
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1874317/ https://ncbi.nlm.nih.gov/pubmed/11874394 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.0306-5251.2001.01541.x |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|